AccuLine Revenue and Competitors
Estimated Revenue & Valuation
- AccuLine's estimated annual revenue is currently $4.5M per year.
- AccuLine's estimated revenue per employee is $263,529
- AccuLine's total funding is $6M.
Employee Data
- AccuLine has 17 Employees.
- AccuLine grew their employee count by 31% last year.
AccuLine's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Co-Founder | Reveal Email/Phone |
2 | Operational Specialist | Reveal Email/Phone |
AccuLine Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.5M | 46 | -23% | N/A | N/A |
#2 | $33.3M | 87 | 24% | N/A | N/A |
#3 | $406.8M | 763 | 23% | N/A | N/A |
#4 | $1M | 5 | 400% | N/A | N/A |
#5 | $1.4M | 18 | 20% | N/A | N/A |
#6 | $137.2M | 288 | 28% | N/A | N/A |
#7 | $142M | 298 | 32% | N/A | N/A |
#8 | $32M | 84 | 29% | N/A | N/A |
#9 | $24.6M | 65 | 30% | N/A | N/A |
#10 | $1.2M | 15 | -6% | N/A | N/A |
What Is AccuLine?
AccuLine was founded with the vision of saving millions of lives worldwide by preventing the next heart attack. AccuLine is developing CORA – an accurate, non-invasive, and cost-effective exam for early detection of CAD. AccuLine's user-friendly exam includes a four-minute measurement of vital signs designed to replace inaccurate, time-consuming, and labor-intensive ergometry exams. This approach addresses the limitations of existing tools in accuracy, invasiveness, and cost. AccuLine has received grants from Google and the Israeli Innovation Authority, and among its shareholders are Mayo Clinic, eHealth Ventures and Maccabi Healthcare Services.
keywords:N/A$6M
Total Funding
17
Number of Employees
$4.5M
Revenue (est)
31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.5M | 17 | -11% | N/A |
#2 | $1M | 17 | 0% | $25M |
#3 | $1.5M | 17 | -37% | N/A |
#4 | $1.2M | 17 | 13% | N/A |
#5 | $2.2M | 17 | -6% | N/A |